Monday, 11 April

  • EDUW 1 – 14.00-15.00 SIEMENS HEALTHINEERS | Room 1
    Title: High Sensitivity cardiac Troponin I: Central lab or POC, the choice is yours
    Chair: Alessandro Ortisi – Siemens Healthineers, Associate Director Global Clinical Marketing
    Johannes Neumann, MD – Department of Cardiology, University Heart and Vascular Center Hamburg, German Center for Cardiovascular Research (DZHK), Hamburg, Germany
    Title: Evaluation of patients with suspected myocardial infarction
    Nils A. Sörensen MD – Department of Cardiology, University Heart and Vascular Center Hamburg, German Center for Cardiovascular Research (DZHK), Hamburg, Germany
    Title: High-sensitivity point-of-care troponin testing
    Learning Objectives:
    • Understand diagnostic steps required in patients with suspected myocardial infarction
    • Learn about diagnostic algorithms using high-sensitivity troponin assays
    • Learn about novel diagnostic strategies using point-of-care assays
  • EDUW 3 – 14.00-15.00 ABBOTT | Room 13a
    Title: Novel Blood Tests for Game-Changing Detection and Treatment of Traumatic Brain Injury
    Chair: Dr. Alex Carterson – DVP Medical, Clinical and Scientific Affairs, Abbott
    Peter Biberthaler, MD – Chair, Department of Trauma Surgery, Technical University Munich
    Title: Diagnostic Dilemma of mild Traumatic Brain Injury
    Beth McQuiston, MD – Senior Medical Director, Abbott
    Title: Traumatic Brain Injury: State of the Art Management
    Learning objectives:
    • Recognize the crucial unmet need for improved brain health assessment
    • Appreciate the objective value of GFAP (Glial Fibrillary Acidic Protein) and UCH-L1 (plasma ubiquitin C-terminal hydrolase-L1) as new game-changing tests that help clinicians evaluate the brain and optimize care pathways for traumatic brain injury
    • Identify collaborative opportunities to achieve measurably better outcomes related to TBI (Traumatic Brain Injury) for patients, payors clinicians and health systems.
  • EDUW 4 – 14.00-15.00 SYSMEX | Room 13b
    Title: Providing clinical answers with innovative technology
    Chair: Dr. Ondrej Valina – Sysmex Europe GmbH
    PD Dr. Mathias Zimmermann, DRK Kliniken Berlin, Germany
    Prof. Johan Elf, University Uppsala, Sweden
    Learning objectives: Sysmex as an IVD manufacturer is aware about diagnostic challenges of clinicians in everyday routine. This workshop will review the current practice in infection diagnostics (performance and availability of biomarkers and lab tests) and present products and technologies from haematology and point-of care that can close gaps in diagnostic information. The learning objective is to create awareness for already available and future innovative products with the aim to improve healthcare.
  • EDUW 5 – 14.00-15.00 ROCHE | Room 14a
    Title: Pandemic Preparedness
    Chair: Dr. Christian Simon, Roche Diagnostics
    Speakers: Andreas Wieser, Global Health & Infectious Diseases at the Medical Center of the University of Munich
    Title: Fighting Emerging Pathogens – the COVID Pandemic response in Germany Stefan Holdenrieder, Director of the Institute of Laboratory Medicine, German Heart Center of the Technical University Munich
    Title: Diagnostic follow-up in a post vaccine setting
    Learning objectives:
    We’re now almost two years on since the COVID-19 pandemic first hit and yet great uncertainty remains. Whilst there has been huge progress in terms of vaccine development and administration, less than a third of the world’s population has received one or more doses of a SARS-CoV-2 vaccine, and there is great variation between countries. As new strains of the virus develop, we must aim for complete vaccine coverage, else we leave ourselves collectively exposed. And as the virus adapts, so must our communal response. To date we have led with social distancing measures and lockdown legislations, but reliable antibody testing enables widespread mass screening that – in combination with local and national policies – can modify and optimize restriction strategies. The information collected can also help scientists assess the exposure of different populations and levels of disease burden so that they can begin to predict its spread. The resulting insights can be used to inform strategies aiming to further contain and counter the virus, optimize governmental responses and ready health services so they are better able to cater to the needs of the people they serve.
  • EDUW 6 – 15.30-16.30 MINDRAY | Room 5
    Title: The pre-classification of digitized images from peripheral blood
    Chairs: Giuseppe D’Onofrio – Università Cattolica del Sacro Cuore, Rome, Italy
    Francesca Mancini – Policlinico Umberto 1, Rome, Italy
    Gina Zini – Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
    Title: The pre-classification of digitized images from peripheral blood
    Learning objective:
    Morphological evaluation of peripheral blood (PB) and bone marrow (BM) blood cells through optical microscopic (OM) examination remains a cornerstone in hematological diagnosis.
    The development of digitized cell images technology and the current availability of systems capable of pre-classifying digitized blood cell images from PB smears offers practical possibilities of clinical applications and new opportunities in the hematology laboratory practice.
    In this workshop comparison between morphology under OM and digitized morphology pre-classification on PB smears from onco-hematological patients will be presented.
  • EDUW 7 – 15.30-16.30 SYSMEX | Room 13a
    Title: Let your lab workflow. Striving for operational excellence.
    Chair: Maros Heidinger – Sysmex Europe GmbH
    Rexhina Cipi, Germany – Sysmex Europe GmbH
    Johanna Engelage, Germany – Sysmex Europe GmbH
    Tanja Tornow, Germany – Sysmex Europe GmbH
    Learning objecticves:
    When designing a specific work area in the laboratory, one of the challenges is to consider the surrounding processes while targeting their significant improvement, and the selection of a specific analyser configuration best possible supporting the key improvement points and KPIs defined by the laboratory. For decades, the Lean methodology has offered the respective tools and procedures for identifying and eliminating waste in processes. This workshop demonstrates the application of the Lean methodology to specific work areas with the aim to identify optimisation potential by eliminating waste and present solutions specifically addressing the identified optimisation potential.
  • EDUW 8 – 15.30-16.30 WATERS | Room 13b
    Title: The role of LC-MS in a clinical laboratory
    Benjamin Dugas, Senior Global Marketing Manager Clinical Diagnostics
    Godo Bosch, Director Strategic Development Clinical Markets, EMEA
    Dietmar Meyer, Project Manager R&D, RECIPE Chemicals + Instruments GmbH
    Learning objectives:
    While Immunoassays play a central role in Clinical Laboratories some needs have required the search for new technologies. We will discuss what Liquid Chromatography with Mass Spectrometry (LC-MS) is, what it brings to the laboratory and how it complements Immunoassays.
    Examples in routine work such as Endocrinology and Therapeutic Drug Monitoring assays will support the discussion. A short look at future possibilities will also be exposed with SARS CoV2 virus measurements.
  • EDUW 9 – 15.30-16.30 SNIBE | Room 14a
    Title: New insights in immunoassays
    Chair: Prof. Mario Plebani
    Prof. Mario Plebani (Department of Laboratory Medicine, University Hospital of Padova, Italy)
    Title: SARS-CoV- 2 antibodies testing: why, when and how?
    Prof. János Kappelmayer (Department of Laboratory Medicine, University of Debrecen, Hungary)
    Title: Experience with AMH and Tacrolimus measurements on the MAGLUMI 800 analyzer
    Learning objectives:
    The main learning objective of the workshop is to offer an update in the field of immunoassays.
    Immunoassays still play a central role in laboratory medicine, but some issues require further efforts:
    • Harmonization and standardization
    • Immunoassays versus mass spectrometry
    • Biological function versus mass concentration: the case of SARS-CoV-2 neutralizing antibodies


Tuesday, 12 April

  • EDUW 15 – 14.00-15.00 ORTHO CLINICAL DIAGNOSTICS| Room 1
    Title: Chimeric Antigen Receptor (CAR)-T cell therapy: research findings, clinical applications, and markers to control cytokine release syndrome
    Chair: Els Melis, EMEA Senior Marketing Manager Clinical Labs Assays, Ortho Clinical Diagnostics
    Prof. Álvaro Urbano Ispizua, Director of the Institute of Hematology and Oncology of Hospital Clínic Barcelona and Full Professor of Medicine at the University of Barcelona.
    Title: Chimeric Antigen Receptor (CAR) – T cell therapy: from immunotherapy research to clinical applications in cancer treatment.
    Cecilia Scarponi, EMEA Clinical Liaison, Ortho Clinical Diagnostics
    Title: Laboratory biomarkers for the investigation of CAR-T cells toxicity.
    Learning objectives:
    • The immunotherapy: mechanisms of action and targeted hematological malignancies
    • The Patient: successful treatments and strategies to overcome side effects
    • How laboratory tests can contribute to a favorable patient outcome? Which biomarkers are currently of interest to assess cytokine release syndrome and neurotoxicity associated with CAR-T cell therapy?
  • EDUW 17 – 14.00-15.00 ABBOTT| Room 13a
    Title: Achieving Measurably Better Healthcare… How to get started and achieve success through integrated clinical care initiatives
    Tricia Ravalico – Director, Scientific Leadership and Education for Abbott, Core Diagnostics Executive Lead, UNIVANTS of Healthcare Excellence Program
    Maria Salinas, PhD – Head of Laboratory, Hospital Universitari Saint Joan d’Alacant, Spain- 2020 UNIVANTS of Healthcare Excellence Global Winner
    Rana Nabulsi, MD – Head Consultant on Healthcare Quality, Dubai Health Authority, UAE – 2020 UNIVANTS of Healthcare Excellence Awards, Global Distinction and Best of the Middle East
    Learning objectives:
    • Recognize, appreciate and emulate critical success factors and key attributes across successful integrated clinical care teams
    • Define relevant key performance indicators that can be influenced and impacted by laboratory medicine and pathology leadership
    • Highlight successful examples of award-winning best practices related to the Diabetes epidemic and COVID-19 pandemic.
    • Identify opportunities to achieve and be recognized for measurably better healthcare performance
  • EDUW 18 – 14.00-15.00 SYSMEX| Room 13b
    Title: Towards a smarter lab with digitally enhanced solutions
    Chair: Theo Hofman – Sysmex Europe GmbH
    Dr. Jean-Marc Giannoli – Biogroup Laboratories, Neuville-sur-Saône, France
    Title: Value of combining QC and patient results for decision support on analytical performance
    Dr. Patrick Cohen – Geneva University Hospital, Switzerland
    Title: Biomedical insights beyond the numbers
    Koray Yurdakul, Sysmex Turkey
    Title: Leveraging virtual and mobile learning experiences in healthcare
    Learning objectives:
    In the laboratory of today, besides global challenges, many regulatory and organisational demands impact the daily work. Oftentimes it can be perceived as a burden, but it also gives new opportunities to improve the laboratory’s quality, streamline processes and find ways to do things differently. With digitally enhanced solutions, information from multiple sources can be consolidated easily for a more holistic approach and lead to new insights. In this workshop, the synergy between existing and new cornerstones of monitoring the quality of analytical processes is demonstrated, explained how the use of expert software can support in clinical decision making and in which ways digital learning experiences can bring and maintain the knowledge of the laboratory staff on a high level while saving time and costs and reduce environmental impact.
  • EDUW 19 – 14.00-15.00 ROCHE| Room 14a
    Title: Diagnostic Innovation Drivers
    Chair: Victor Jeger, PD MD, PhD, Roche Diagnostics
    Prof. Dr. med. Michael Vogeser, Institute of Laboratory Medicine, Hospital University of Munich, Germany
    Title: Use of Mass Spectrometry in Clinical Diagnostics
    Prof. Prof. Charlotte Teunissen, Universitair Medische Centra Amsterdam, The Netherlands
    Title: Timely and accurate differential diagnosis of patients with cognitive impairment
    Learning objectives:
    Mass spectrometry is a powerful analytical technology that has evolved from a research tool to a complementary platform in routine clinical laboratories. Unlike established methods such as immunoassays, MS allows true multiplexing, highest specificity of detection and unsurpassed reliability due to the use of standard compounds labelled with stable isotopes. With increasing clinical applications, the focus is on clinical chemistry and more recently microbiology. The main objective of this presentation is to give an overview of the current and developing clinical applications of MS.
    Dementia affects millions of people worldwide and is expected to triple by 2050. Alzheimer’s disease (AD) is the most common form of dementia and may contribute to 50-60% of cases. In 2015 the overall global cost of dementia was already USD 818 billion and is expected to increase to USD 2 trillion in 2030. Early diagnosis can benefit patients and society as a whole. Confirming a diagnosis of mild cognitive impairment (MCI) and Alzheimer’s disease (AD) is important and often a relief for the individual and their loved ones. Receiving a diagnosis early enables patients to make changes to their diet and lifestyles which may slow the decline in their cognitive functions. Two of the main hallmark signs of AD are the “plaques” and “tangles” that develop in the brain, caused by the build-up of, respectively, amyloid and tau proteins. The accumulation of amyloid beta and tau starts decades prior to symptom onset. CSF biomarkers support early and accurate diagnosis of MCI and AD, as these biomarkers reflect the specific pathological accumulation of amyloid beta in plaques and tau in neurofibrillary tangles.
  • EDUW 20 – 15.30-16.30 MINDRAY| Room 5
    Title: Presepsin and new generation inflammatory biomarkers in COVID-19 and other infections
    Chairs: Massimiliano M. Corsi Romanelli – Università degli Studi di Milano, Milan, Italy
    Antonio Brattoli – Mindray Medical Italy S.R.L., Milan, Italy
    Emanuela Galliera – Università degli Studi di Milano, Milan, Italy
    Title: Presepsin and new generation inflammatory biomarkers in COVID-19 and other infections
    Learning objectives:
    The appropriate identification of infection is the basis for effective treatment and control of infective diseases. Presepsin (PSP), an emerging biomarker of infection, has been recently described as early marker of different infections.
    This workshop will present the evaluation of Presepsin, in correlation with new inflammatory markers, cytokine storm molecules and current inflammatory parameters (IL-6, IL-10, SuPAR and sRAGE), in order to define a panel of biomarkers that could be useful for a better prognostic prediction of COVID-19 mortality.
  • EDUW 21 – 15.30-16.30 GMT Science| Room 13a
    Title: Faecal metagenomics analysis made available at the medical lab to empower clinical diagnosis & management
    Chair: Etienne Formstecher – CEO, GMT, Paris, France
    Fay Betsou – Scientific Advisor, Laboratoire National de Santé, Luxembourg
    Title: In practice: setting up faecal metagenomics analyses at the medical laboratory
    Francisco Guarner – Member of the Digestive System Research Unit, University Hospital Vall d’Hebron; Consultant of Gastroenterology, Teknon Medical Centre, Barcelona, Spain
    Title: Microbiota: a key player in physiology and pathophysiology
    Learning objectives:
    The gut microbiota is now recognized as a novel therapeutic target in many clinical contexts.
    However, due to the lack of a reliable tool to characterize it, the proposed treatments can neither be adapted to the specific needs of the patient nor evaluated in terms of response.
    The educational workshop will present how analysis of the faecal metagenome at the medical laboratory is now possible thanks to the combination of reliable, standardized and reproducible pre-analytical and analytical techniques with robust bioinformatics methods. By putting in place this solution, , medical laboratories can empower clinical diagnosis and management in various situations, including very common ones at the medical consultation where patients express gut complaints.
  • EDUW 22 – 15.30-16.30 SEBIA| Room 13b
    Title: What’s new in Minimal Residual Disease testing for Multiple Myeloma?
    Chair: Dr. Martijn VAN DUIJN, Erasmus Medical Center, Rotterdam, The Netherlands
    Dr. Thomas DEJOIE, Biochemical Laboratory, University Hospital of Nantes, France
    Title: Overview of MRD testing in Myeloma and current needs
    Dr. Hans JACOBS, Radboud University Medical Center, Nijmegen, The Netherlands
    Title: Mass spectrometry as a tool for MRD detection in the blood of Myeloma patients
    Learning objectives:
    • Why do we need MRD for patients?
    • How do we process MRD in 2021?
    • Why do we need alternative to the MRD bone marrow evaluation?
    • Understand the principle of mass spectrometric measurements of clonotypic peptides
    (bottom-up MS).
  • EDUW 23 – 15.30-16.30 SNIBE| Room 14a
    Title: An update on tumor markers from the general aspects to their clinical uses
    Chair: Prof. Tomris Ozben
    Prof. Tomáš Zima (Institute of Clinical Chemistry & Laboratory Diagnosis. First Faculty of Medicine Charles University Prague – Czech Republic)
    Title: Classification of tumor markers. Characteristics of ideal tumor markers
    Prof. Tomris Ozben (Dept. of Clinical Biochemistry, Medical Faculty, University of Akdeniz, Antalya, Turkey)
    Title: Methods to measure tumor markers. Clinical uses of tumor markers for malignant diseases
    Learning objectives:
    Tumor markers are used to determine risk, screen for early cancers, establish diagnosis, follow prognosis, predict the efficiency of a specific therapy, and monitor for disease recurrence.
    • Classification of tumor markers based on category, origin, structure, biological function in tumor growth or formation
    • Characteristics of ideal tumor markers
    • Methods to measure tumor markers
    • Limitations of tumor marker tests
    • Benign conditions associated with rise in tumor markers
    Clinical uses of tumor markers for malignant diseases (clinical cases)
  • EDUW 26 – 17.00-18.00 SIEMENS HEALTHINEERS| Room 13b
    Title: Non-Invasive Assessment of Liver Fibrosis in Chronic Liver Diseases
    Chair: Jean Charles Clouet – Siemens Healthineers, EMEA Clinical Marketing
    Professor Jörn M. Schattenberg – Metabolic Liver Research Program, University Medical Center Mainz
    Learning Objectives:
    • Educate on the current growing burden of disease due to NAFLD/NASH
    • Learn how non-invasive testing can help identify patients at risk of NASH progression
    • Understand how clinicians can implement available patient pathways to improve referrals and decrease costs


Wednesday, 13 April

  • EDUW 29 – 14.00-15.00 ORTHO CLINICAL DIAGNOSTICS | Room 1
    Title: Sustainable Laboratory Medicine: Prepare for the future now!
    Chair: Dr. Bernard Gouget, Ph.D – ex-Assistant Professor, University Hospital in Paris Descartes. President-Healthcare Division Executive Committee, Comité Français d’accréditation (Cofrac), President, National Committee for the selection of Reference Laboratories, Ministry of Health
    Professor Damien Gruson – Head of the department of Laboratory Medicine of the Cliniques Universitaires Saint Luc – Brussels, Belgium
    Title: Sustainable Laboratory Medicine: Myth or reality?
    Jordi Trafí-Prats – Senior Director EMEA Marketing at Ortho Clinical Diagnostics
    Title: Sustainable Laboratory Medicine: we all have a role to play.
    Learning objectives:
    In the coming years, the impact of sustainability will be increasingly felt in healthcare. From the implications of legislation to the growing number of environmentally conscious investors, this is a topic which is set to shape the future direction of hospitals, labs and blood banks.
    Professor Damien Gruson as a member of the Division on Emerging Technologies of IFCC, is sharing his perspective and will be providing some pragmatic approaches and share experiences from the perspective of the Clinical Laboratory. Jordi Trafí-Prats will demonstrate how the industry can and should contribute to assure Laboratories are equipped with sustainable solutions.
  • EDUW 31 – 14.00-15.00 ABBOTT | Room 13a
    Title: Driving Healthcare Transformation Through Clinical Decision Support
    Dr Janne Cadamuro – Department of Laboratory Medicine, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria
    Title: How to tackle laboratory underuse using Clinical Decision Support Systems (CDSS)
    Francoise Luyckx – Pharmacist biologist, Laboratory Manager and Coordinator of new projects, member of the “Artificial Intelligence” working group, Coordinator of CDS project and IT trainer, University Hospital of Liege (CHU de Liège), Belgium
    Romy Gadisseur – Pharmacist biologist, Head of the Laboratory of Automated Biochemistry, Department of Clinical Chemistry, University Hospital of Liege (CHU de Liège), Belgium
    Title: CHU Liege: Impacting CKD patients by leveraging a Clinical Decision Support
    Abbott Speaker
    Florian Lange, Director AlinIQ & Enterprise Solutions EMEA
    Title: Transformation of healthcare through digital solutions
    Learning objectives:
    • Recognize the value of clinical decision support and artificial intelligence in achieving measurable better healthcare.
    • Understand how the use of a clinical decision support solution enabled the University Hospital of Salzburg and in CHU Liege to address unmet needs for microcytic anaemia, diabetes and chronic kidney disease.
    • Connect the dots on how to get started and drive digital transformation into better healthcare outcomes
  • EDUW 32 – 14.00-15.00 SIEMENS HEALTHINEERS | Room 13b
    Title: The Evolving Role of Artificial Intelligence in Laboratory Testing
    Raj Gopalan, MD, MSIS, Head of Global Clinical Decision Support and Chief Medical Informatics Officer, Siemens Healthineers, Tarrytown, NY, USA
    Sarah Wheeler, Assistant Professor, PhD, FACB, CC, Associate Medical Director, Clinical Immunopathology; Medical Director, Automated Laboratory, UPMC Mercy; and Medical Director, Automated Laboratory, Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA
    Learning Objectives:
    • Define artificial intelligence and machine learning in the context of laboratory medicine.
    • Discuss the relevance of artificial intelligence and machine learning in laboratory medicine and diagnostics.
    • Understand the potential value of artificial intelligence in laboratory diagnostics.
  • EDUW 33 – 14.00-15.00 ROCHE | Room 14a
    Title: Diabets and the heart
    Chair: Rolf Hinzmann, MD, PhD, Head of Medical Science – Roche Diabetes Care, Mannheim, Germany
    Prof. Christophe Meune, M.D., PhD, Cardiology Department, Avicenne University Hospital, Paris, France
    Title: Early identification of Heart Failure in T2D; Intervention for improving patient outcomes
    Prof.Dr. Stephan Jacob – Praxis für Prävention und Therapie, Villingen-Schwenningen, Germany
    Title: Integrated Personal Diabetes Management
    Learning Objectives:
    For many years, clinical studies could not show that lowering glucose in patients with type 2 diabetes leads to better macrovascular outcomes. In the past few years, new data have shown that treatment with two classes of dugs developed as “glucose-lowering agents,” SGLT2 inhibitors and GLP-1 receptor agonists can reduce macrovascular and renal complications. These studies have prompted debate about the main aim of type 2 diabetes management. In this scientific session eras of diabetes management are described according to the treatment recommendations, moving from a pure glucocentric view into the present cardio-renal outcome-oriented approach, this has been endorsed by major diabetes and cardiology societies. Type 2 Diabetes Patients are at high risk of developing cardiovascular disease. New evidence on the use of natriuretic peptides supports the identification of patients with high cardiovascular risk, for risk stratification and optimization of cardio protective treatment.
  • EDUW 35 – 15.30-16.30 BD | Room 13a
    Title: Preanalytical POCT Errors – What impact do they have?
    Chair: Dr Brendan Meyer – Senior Manager, Medical Affairs Europe, Integrated Diagnostic Solutions, BD Life Sciences
    Prof Peter Luppa – Institute for Clinical Chemistry and Pathobiochemistry, Technische Universität München, Munich, Germany
    Dr Andrei Tintu – Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands
    Dr Antonio Buño Soto – Pathology Department, La Paz Hospital, Madrid, Spain
    Learning objectives:
    • There are erroneous POCT results due to blood sample quality, which are not detected by the POCT device.
    • How preanalytical errors not detected by the POCT device can impact on patient care.
    • POCT preanalytical errors can impact on hospital resources and budgets